NN 7128

Drug Profile

NN 7128

Alternative Names: GlycoPEGylated Factor VIIa - Novo Nordisk; LA-rFVIIa - Novo Nordisk; N7-GP; NN7128; NNC 0128-0000-2011; NNC 0128-0000-2021; rFVIIa long-acting analogue - Novo Nordisk

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Blood coagulation factors; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemophilia

Most Recent Events

  • 26 Jan 2011 Novo Nordisk initiates a phase I trial for Haemophilia in the UK (NCT01272206)
  • 03 Jun 2008 Adverse events data from a phase I trial in Haemophilia released by Novo Nordisk
  • 03 Jun 2008 Novo Nordisk completes an initial phase I trial in Haemophilia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top